Antibiotic and antimicrobial candidates fail for many reasons long before later-stage development: weak activity against priority strains, poor bactericidal performance, limited coverage of resistant isolates, loss of potency in biologically relevant media, and large gaps between planktonic and biofilm behavior. BOC Sciences provides comprehensive antibiotic and antimicrobial testing services to help sponsors generate decision-ready microbiology data across discovery and preclinical research. Our platform integrates MIC and MBC determination, time-kill kinetics, checkerboard synergy studies, resistance risk assessment, biofilm efficacy testing, and customized strain-panel design for small molecules, peptides, natural-product derivatives, and novel anti-infective modalities. Whether you are advancing a new scaffold from custom antibiotic synthesis or refining candidates after high-throughput screening, we deliver clear experimental strategies, rigorous execution, and actionable interpretation aligned with your program goals.
We establish robust baseline potency using standardized broth-based and customized susceptibility workflows, generating reproducible quantitative data for candidate comparison and hit triage.
Static endpoint values rarely answer how fast or how durably a molecule works. We add kinetic and combination assays to clarify bactericidal behavior and interaction patterns.
For many anti-infective programs, planktonic susceptibility alone is not enough. We evaluate antimicrobial performance in harder-to-treat bacterial states and phenotype-driven models.
We help teams understand whether promising activity is likely to hold up under repeated microbial challenge and whether the signal remains selective in broader research packages.
BOC Sciences combines microbiology expertise, tailored strain panels, and decision-focused reporting to accelerate antibiotic and antimicrobial evaluation.
We use scalable microplate-based workflows for MIC, MBC, and checkerboard studies, enabling consistent concentration design, efficient replicate handling, and straightforward cross-candidate comparison.
For bactericidal and time-kill studies, automated counting and structured dilution workflows improve data integrity and support precise log-reduction analysis across multiple time points.
We combine optical density, viable count, fluorescence, metabolic markers, and microscopy-based outputs to build a fuller picture of antimicrobial effect and mechanism-relevant behavior.
Static and customized biofilm assay formats support evaluation of inhibition, biomass disruption, and eradication performance where conventional planktonic tests may underestimate development risk.
Serial exposure designs, fold-shift tracking, and isolate-specific analysis help determine how rapidly susceptibility may change and which candidates merit further optimization.
Reports are organized around development decisions, including assay rationale, strain selection, concentration design, raw observations, calculated endpoints, and practical interpretation for next-step planning.
Our testing services support diverse anti-infective modalities and project stages, from early screening to advanced comparative profiling. We adapt assay design to molecular class, target organism, and intended research question rather than forcing every program into a single template.
Share your compound class, target organisms, and decision points. Our team will build a testing plan that connects potency, kinetics, biofilm behavior, and resistance risk into one coherent package.
We review compound class, target pathogens, expected mode of action, formulation constraints, and key go/no-go questions to define the right assay sequence, strain panel, and concentration framework.
Our scientists establish inoculum conditions, media selection, exposure windows, readout strategy, and solubility-aware handling procedures so that observed activity reflects the candidate rather than avoidable assay artifacts.
We run potency, bactericidal, kinetic, combination, resistance, and biofilm studies in a logical progression, expanding only where the data suggest real value for candidate advancement or differentiation.
You receive a structured report with endpoint values, assay observations, comparative interpretation, and practical recommendations for lead ranking, mechanism follow-up, or broader preclinical evaluation.
A single MIC value can look promising while still hiding slow kill kinetics, weak bactericidal effect, or unstable performance against resistant isolates. We address this by connecting MIC results with MBC, time-kill, and expanded strain-panel studies, so teams can judge whether a candidate is truly advancing or only appearing attractive in a narrow assay window.
Many candidates perform adequately against planktonic bacteria yet lose impact against structured biofilm communities. BOC Sciences designs MBIC and MBEC workflows, viability measurements, and imaging-supported assessments that reveal whether a molecule can inhibit formation, reduce biomass, or contribute to eradication-oriented strategies.
Programs can lose momentum when resistance liabilities appear late. Our serial passage and susceptibility-shift studies help identify risk earlier, allowing medicinal chemistry and screening teams to refine scaffold direction before committing to larger downstream packages.
Combination strategies are often explored when single-agent performance is incomplete, but weak assay design can produce ambiguous conclusions. We apply checkerboard and confirmatory kinetic approaches to clarify whether two agents show complementary, neutral, or counterproductive behavior under meaningful experimental conditions.
From susceptibility profiling to resistance-risk studies, BOC Sciences helps antibiotic innovators move from isolated assay results to stronger development decisions.
We align assays with sponsor decisions such as hit triage, lead differentiation, combination selection, and resistance de-risking rather than delivering disconnected microbiology endpoints.
Study packages can include reference strains, resistant isolates, and biofilm-forming organisms relevant to your antibacterial hypothesis and intended application area.
Our team considers kill kinetics, concentration behavior, and phenotype-specific response patterns to help explain why candidates succeed, plateau, or diverge.
Deliverables are structured to support medicinal chemistry, biology, and project management teams with data tables, assay logic, interpretation notes, and recommended follow-up directions.
Client Needs: A sponsor developing a cationic heteroaromatic series for Gram-negative pathogens needed to rank twelve analogs after preliminary potency signals, but internal datasets did not explain which compounds were truly bactericidal.
Challenges: Several analogs shared similar MIC values while showing different solubility behavior and inconsistent colony recovery, making advancement decisions uncertain.
Solution: BOC Sciences designed a tiered testing package including MIC, MBC, and multi-time-point kill-curve studies against a focused panel of Enterobacterales and non-fermenting strains. We incorporated concentration-normalized CFU analysis, replicate-supported data review, and side-by-side interpretation of inhibitory versus bactericidal separation to clarify compound ranking and support more confident lead selection.
Outcome: Three analogs were deprioritized despite acceptable MICs because kill kinetics plateaued early, while two leads showed clearer bactericidal performance and stronger differentiation for medicinal chemistry follow-up.
Client Needs: A peptide-based antimicrobial program targeting device-associated infection wanted to know whether strong planktonic activity would translate into meaningful anti-biofilm performance.
Challenges: Standard susceptibility data did not address structured biofilm tolerance, and the client needed a realistic comparison across inhibition, biomass reduction, and eradication-related endpoints.
Solution: We established biofilm formation and treatment workflows using a Staphylococcus-dominant model, then performed MBIC and MBEC testing together with biomass staining, viable count determination, and microscopy-supported endpoint review. This workflow enabled a more practical comparison of anti-biofilm behavior across treatment stages and helped distinguish partial suppression from deeper biofilm control.
Outcome: The data showed one peptide variant maintained superior biofilm suppression at lower multiples of planktonic MIC, giving the client a clear path for formulation and surface-application research.
Client Needs: A project team exploring a beta-lactam partner strategy for a resistant isolate panel needed evidence on whether the second agent delivered real enhancement or only additive noise.
Challenges: Internal screening suggested occasional improvement, but the effect was not consistent enough to justify broader investment without more rigorous interaction data.
Solution: BOC Sciences carried out checkerboard analysis across multiple isolate backgrounds and then confirmed the most promising concentration pairs through time-kill experiments. We compared interaction patterns by isolate type and exposure level rather than relying on a single summary metric alone, allowing the client to identify where combination benefit was reproducible and where apparent gains were strain-dependent.
Outcome: The client identified a narrower but credible combination window, refined its strain-selection strategy, and avoided further work on concentration ranges that did not produce meaningful benefit.
Antibiotic and antimicrobial testing evaluates how effectively a compound, formulation, extract, peptide, polymer, or material inhibits or kills target microorganisms under controlled laboratory conditions. For drug development teams, these studies help identify promising active candidates, compare structure-activity trends, characterize spectrum of activity, and generate decision-support data before deeper optimization. BOC Sciences supports antimicrobial discovery programs with flexible in vitro testing solutions, helping clients assess antibacterial and antifungal activity across early screening, hit validation, and lead optimization workflows.
Minimum inhibitory concentration, or MIC, is one of the most widely used quantitative readouts in antimicrobial evaluation because it indicates the lowest tested concentration that visibly inhibits microbial growth under defined assay conditions. For drug developers, MIC data can help rank candidate potency, compare analogs, guide medicinal chemistry decisions, and prioritize compounds for follow-up studies. When combined with complementary assays, MIC testing provides a practical foundation for understanding whether a candidate has sufficient activity to justify continued development investment.
Common antimicrobial testing methods include broth microdilution, agar dilution, disk diffusion, time-kill studies, checkerboard assays, biofilm inhibition assays, and custom growth-inhibition formats. The best method depends on the sample type, target organism, expected activity profile, solubility behavior, and development question being asked. BOC Sciences can help design fit-for-purpose testing strategies for small molecules, peptides, natural products, polymers, and other antimicrobial candidates, enabling clients to obtain relevant data rather than relying on a one-size-fits-all assay.
Antimicrobial testing supports drug discovery by translating compound ideas into measurable biological performance data. Early screening can identify active hits, dose-response studies can show potency trends, and expanded panel testing can clarify whether activity is narrow, broad, or organism-specific. Additional assays may explore bacteriostatic versus bactericidal behavior, combination potential, resistance-related concerns, or biofilm activity. For professional R&D teams, this information reduces uncertainty, supports rational prioritization, and helps align chemistry, biology, and formulation decisions around the most promising antimicrobial candidates.
Drug developers should look for an antimicrobial testing partner with strong microbiology expertise, adaptable assay design, clear communication, and the ability to support different sample types and research objectives. A useful partner should understand early discovery questions, not only routine testing workflows, and should help clients select assays that match the development stage and target profile. BOC Sciences offers integrated drug development service capabilities, allowing clients to connect antimicrobial testing with broader chemistry, analysis, and discovery support for more coordinated project execution.
BOC Sciences generated a clear and highly reproducible MIC dataset for our novel antibacterial lead across a challenging Gram-positive panel. Their team helped us compare potency shifts between analogs and quickly identify the most promising series for further optimization.
— Antimicrobial Discovery Lead, Emerging Biotech
We required antimicrobial testing against relevant resistant isolates, not just standard laboratory strains. BOC Sciences built a thoughtful study plan, delivered well-structured results, and gave us valuable insight into spectrum, potency, and candidate differentiation.
— Project Manager, Pharmaceutical R&D Organization
Their antibiotic testing workflow fit perfectly with our medicinal chemistry cycle. By combining susceptibility testing with practical interpretation of the data, BOC Sciences enabled our team to make faster SAR decisions and prioritize compounds with real development potential.
— Senior Scientist, Small Molecule R&D, Drug Discovery Company
Beyond routine screening, BOC Sciences helped us understand how our antimicrobial candidate behaved over time under different exposure conditions. Their time-kill and follow-up testing gave us a much stronger picture of bactericidal activity and dose-dependent performance.
— Head of Preclinical Evaluation, Biopharmaceutical Company
Client identities are anonymized to protect confidentiality.
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
